Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy

References

• Shurin MR. Cancer as an immune-mediated disease. ImmunoTargets and Therapy 2012; 1:1 - 6; http://dx.doi.org/10.2147/ITT.S29834
   PubMedGoogle Scholar
• Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4:401 - 11; http://dx.doi.org/10.1038/nrc1359; PMID: 15122211
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475 - 80; http://dx.doi.org/10.1038/nm1039; PMID: 15122249
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265 - 77; http://dx.doi.org/10.1038/nrc3258; PMID: 22437871
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52 - 8; http://dx.doi.org/10.1038/nm0196-52; PMID: 8564842
   PubMed Web of Science ®Google Scholar
• Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 2011; 7:579 - 84; http://dx.doi.org/10.4161/hv.7.5.14652; PMID: 21422813
   PubMed Web of Science ®Google Scholar
• Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012; 14:647 - 56; PMID: 22686130
   PubMed Web of Science ®Google Scholar
• Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56:1513 - 37; http://dx.doi.org/10.1007/s00262-007-0334-z; PMID: 17503040
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7:109; http://dx.doi.org/10.1186/1479-5876-7-109; PMID: 20021667
   PubMed Web of Science ®Google Scholar
• Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001; 194:1013 - 20; http://dx.doi.org/10.1084/jem.194.7.1013; PMID: 11581322
   PubMed Web of Science ®Google Scholar
• Saikh KU, Khan AS, Kissner T, Ulrich RG. IL-15-induced conversion of monocytes to mature dendritic cells. Clin Exp Immunol 2001; 126:447 - 55; http://dx.doi.org/10.1046/j.1365-2249.2001.01672.x; PMID: 11737061
   PubMed Web of Science ®Google Scholar
• Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol 2004; 34:66 - 73; http://dx.doi.org/10.1002/eji.200324567; PMID: 14971031
   PubMed Web of Science ®Google Scholar
• Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 2005; 78:656 - 64; http://dx.doi.org/10.1189/jlb.1104631; PMID: 15961574
   PubMed Web of Science ®Google Scholar
• Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 2007; 37:1678 - 90; http://dx.doi.org/10.1002/eji.200636329; PMID: 17492620
   PubMed Web of Science ®Google Scholar
• Hardy MY, Kassianos AJ, Vulink A, Wilkinson R, Jongbloed SL, Hart DN, et al. NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunol Cell Biol 2009; 87:606 - 14; http://dx.doi.org/10.1038/icb.2009.44; PMID: 19546878
   PubMed Web of Science ®Google Scholar
• Harris KM. Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol 2011; 90:727 - 34; http://dx.doi.org/10.1189/jlb.0311132; PMID: 21724805
   PubMed Web of Science ®Google Scholar
• Hanke NT. Molecular Regulation of the Tumor Killing Activity of Dendritic Cells. PhD dissertation 2012; The University of Arizona, Tucson, AZ, USA.
   Google Scholar
• Anguille S, Lion E, Tel J, de Vries IJ, Couderé K, Fromm PD, et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One 2012; 7:e51851; http://dx.doi.org/10.1371/journal.pone.0051851; PMID: 23284789
   PubMedGoogle Scholar
• Celli S, Day M, Müller AJ, Molina-Paris C, Lythe G, Bousso P. How many dendritic cells are required to initiate a T-cell response?. Blood 2012; 120:3945 - 8; http://dx.doi.org/10.1182/blood-2012-01-408260; PMID: 22995897
   PubMed Web of Science ®Google Scholar
• Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26:2186 - 96; http://dx.doi.org/10.1038/leu.2012.145; PMID: 22652755
   PubMed Web of Science ®Google Scholar
• Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009; 20:1106 - 18; http://dx.doi.org/10.1089/hum.2009.145; PMID: 19656053
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824 - 9; http://dx.doi.org/10.1073/pnas.1008051107; PMID: 20631300
   PubMed Web of Science ®Google Scholar
• Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med 2010; 8:90; http://dx.doi.org/10.1186/1479-5876-8-90; PMID: 20920165
   PubMed Web of Science ®Google Scholar
• Romano E, Cotari JW, Barreira da Silva R, Betts BC, Chung DJ, Avogadri F, et al. Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood 2012; 119:5182 - 90; http://dx.doi.org/10.1182/blood-2011-09-382200; PMID: 22510877
   PubMed Web of Science ®Google Scholar
• Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology 2013; 2:e23037; http://dx.doi.org/10.4161/onci.23037; PMID: 23524451
   PubMedGoogle Scholar
• Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 2010; 59:1 - 11; http://dx.doi.org/10.1007/s00262-009-0736-1; PMID: 19618185
   PubMed Web of Science ®Google Scholar
• Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines?. Oncologist 2012; 17:1256 - 70; http://dx.doi.org/10.1634/theoncologist.2011-0122; PMID: 22907975
   PubMed Web of Science ®Google Scholar
• Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012; 26:2019 - 26; http://dx.doi.org/10.1038/leu.2012.87; PMID: 22446501
   PubMed Web of Science ®Google Scholar
• Hardy MY. Manipulation of human dendritic cell subsets and the design of optimal preparations for tumour immunotherapy. PhD dissertation 2008; The University of Queensland, QLD, Australia.
   Google Scholar